¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"no observed adverse effect level"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® adverse effect ÇÑ±Û ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
¼³¸í   
  ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§ ³ªÅ¸³ª´Â Ä¡·á¸ñÀû¿¡ ºÎÇÕµÇÁö ¾Ê´Â ºÒÄèÇÑ ÀÛ¿ë, Áï ºÎÀÛ¿ëÀ» ¿ªÈ¿°ú·Î Ç¥ÇöÇϴ °æ¿ì°¡ ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­´Â ¿ªÈ¿°ú¶õ ¡°¿¹¹æ, Áø´Ü, Ä¡·áÀÇ ¸ñÀûÀ¸·Î »ç¶÷¿¡°Ô »ó¿ë·®ÀÇ ¾àÀ» »ç¿ëÇÏ¿´À» ¶§ ¹ßÇöÇϴ Àå¾Ö·Î, ÀǵµÇÏÁö ¾ÊÀº Àۿ롱À̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§, Æ¯È÷ ÁÖ¸ñÇÏ¿©¾ß ÇÒ ÀϹÝÀûÀΠ¿ªÈ¿°ú·Î¼­ ¾à¹°¾Ë·¹¸£±â, Á¶Ç÷Àå±â Àå¾Ö, °£-ÄáÆÏÀÇ Àå¾Ö, ¹°Áú ´ë»ç Àå¾Ö µîÀÌ ÀÖ´Ù. ÀÌ ¿Ü¿¡ ÀÓ»êºÎ¿¡°Ô Åõ¿©ÇÏ¿© ¹ß»ýÇÑ ±âÇü¹ß»ý, ¸¶¾à, °¢¼ºÁ¦, ±âŸ ÇâÁ¤½ÅÁ¦¿¡ ÀÇÇÑ ÀÇÁ¸¼º Çü¼ºµµ Áß¿äÇÏ´Ù.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • no-observed-effect level
    ¹«°üÂûÈ¿°ú¼öÁØ
  • adverse effect
    À¯ÇØÈ¿°ú
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°À¯ÇعÝÀÀ
  • adverse reaction
    À¯ÇعÝÀÀ
  • acceptable noise level
    Çã¿ë¼ÒÀ½¼öÁØ
  • antimicrobial level
    Ç×±Õ¼öÁØ
  • audiometric level
    û·Â¼öÁØ
  • air fluid level
    °ø±â¾×üÃþ
  • alertness level
    °¢¼º¼öÁØ
  • background level
    ¹è°æ¼öÁØ
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½¼öÁØ, ½ÇÁ¦°¨°¢¼ÒÀ½¼öÁØ
  • electronic energy level
    ÀüÀÚ¿¡³ÊÁö¼öÁØ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse effect
    (¢¡ adverse event) À¯ÇذæÇè
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • level
    1. ¼öÁØ, 2. Ãþ, 3. Ä¡, 4. ³óµµ
  • air fluid level
    °ø±â¾×üÃþ
  • peak level
    ÃÖ°íÄ¡
  • sedimentation level
    ħÀüÃþ
  • sound level meter
    ¼ÒÀ½°è
  • effect
    È¿°ú, ÀÛ¿ë
  • anticoagulant effect
    Ç×ÀÀ°íÈ¿°ú
  • antioxidant effect
    Ç×»êÈ­È¿°ú
  • inhibitory effect
    ¾ïÁ¦È¿°ú
  • palliative effect
    ¿ÏÈ­È¿°ú, °æ°¨È¿°ú
  • prolonged effect
    Áö¼ÓÈ¿°ú
  • radiation effect
    ¹æ»ç¼±È¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • no-observed-effect level
    ¹«È¿°ú°üÂû¼öÁØ
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse selection
    ¿ª¼±ÅÃ
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • acceptable noise level
    Çã¿ë¼ÒÀ½¼öÁØ
  • air fluid level
    °ø±â¾×üÃþ
  • alertness level
    °¢¼º¼öÁØ
  • antimicrobial level
    Ç×±Õ¼öÁØ
  • audiometric level
    û·Â¼öÁØ
  • background level
    ¹è°æ¼öÁØ
  • blood enzyme level
    Ç÷ÁßÈ¿¼Ò³óµµ
  • blood oxygenation level dependant contrast
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸´ëÁ¶µµ
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • ADR : adverse drug reaction
    ¾à¹°À¯ÇØÀÛ¿ë(å·ÚªêóúªíÂéÄ).
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
  • adverse reaction
    À¯ÇØ(êóúª)¹ÝÀÀ, ¿ª(æ½)¹ÝÀÀ.
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse reactions
    ºÎÀÛ¿ë
  • adverse selection
    ¿ª¼±ÅÃ.
  • BOLD(blood oxygenation level dependant)
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸
  • EPNDB =effective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§, ½ÇÁ¦°¨°¢¼ÒÀ½
  • EPNDB=ÊÝeffective perceived noise level
    ½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§.
  • acceptable noise level
    Çã¿ë¼ÒÀ½
  • air fluid level
    °ø±â ¾×üÃþ
  • antimicrobial level
    Ç×±ÕÁ¦Ä¡<¼öÁØ(â©ñÞ)>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • observed value
    °üÃøÄ¡(˴̬̬).
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ºÎÀÛ¿ë
  • untoward effect =adverse reaction, unwanted reaction
    À¯ÇعÝÀÀ(êóúªÚãëë), ¾àÇØ(å·úª)¹ÝÀÀ.[¾à¸®]ºÎÀÛ¿ë, ºÒ¿øÀÛ¿ë.
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
  • adverse reaction
    ºÎÀÛ¿ë
  • adverse reaction
    À¯ÇØ(êóúª)¹ÝÀÀ, ¿ª(æ½)¹ÝÀÀ.
  • adverse reactions
    ºÎÀÛ¿ë
  • adverse selection
    ¿ª¼±ÅÃ.
  • drug reactions, adverse
    ¾à¹°¹ÝÀÀ(¡­Úãëë), ºÎÀÛ¿ë(ÜùíÂéÄ)
  • acceptable noise level
    Çã¿ë¼ÒÀ½
  • air fluid level
    °ø±â ¾×üÃþ
  • alertness level
    °æ°è±âÁØ(ÌíÌüÐññÞ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • basal level
    ±âÀú¼öÁØ(Ðñî¼â©ñÞ)
  • high-level promoter
    °íÀ§(ÍÔêÈ)ÇÁ·Î¸ðÅÍ
  • level of significance
    À¯ÀǼöÁØ(êóëòâ©ñÞ)
  • low-level promoter
    ÀúÀ§(î¸êÈ) ÇÁ·Î¸ðÅÍ
  • anomeric effect
    ¾Æ³ë¸Ó¿µÇâ(ç¯úÂ)
  • asymmetry effect
    ºÎÀçÈ¿°ú(Üôî²üùÍý)
  • Blinks effect
    ºí¸°Å©½º È¿°ú(üùÍý) (ÔÒ) chromatic transient
  • Bohr effect
    º¸¾î È¿°ú(üùÍý)
  • charge effect
    ÀüÇÏÈ¿°ú(ï³ùÃüùÍý)
  • chronotropic effect
    º¯½Ã¼ºÈ¿°ú(ܨãÁàõüùÍý)
  • cis effect
    ½Ã½º È¿°ú(üùÍý)
  • Compton effect
    ÄÞÅæ È¿°ú(üùÍý)
  • Cotton effect
    ÄÚÅæ È¿°ú(üùÍý)
  • Coulomb effect
    "Äí·Õ È¿°ú(üùÍý),(ÔÒ) ion-ion interaction"
  • Crabtree effect
    Å©·¡ºêÆ®¸® È¿°ú(üùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse reaction
    ºÎÀÛ¿ë, À¯ÇعÝÀÀ, À¯ÇØÀÛ¿ë, ¿ª¹ÝÀÀ
  • air fluid level
    °ø±â¾×üÃþ
  • blood oxygenation level dependant [=BOLD]
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸
  • blood oxygenation level dependant contrast
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸´ëÁ¶µµ
  • BOLD [=blood oxygenation level dependent]
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸
  • carinal level
    ºÐ±â ´ë
  • fat blood level
    Áö¹æÇ÷Ãþ
  • fluid fluid level
    ¾×ü¾×üÃþ
  • fluid level
    ¾×ü Ãþ, ¼öÀ§
  • level
    ´ë, ¼öÁØ
  • sedimentation level
    ħÀüÃþ
  • window level
    â³ôÀÌ
  • air gap effect
    °ø±â°£°ÝÈ¿°ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NOAEL no observed adverse effect level
NOEL no observed effect level
SL sarcolemma; sclerosing leukoencephalopathy; secondary leukemia; segment length; sensation level; sen...
AE above-elbow [amputation]; acrodermatitis enteropathica; activation energy; adult erythrocyte; advers...
NARL no adverse response level
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LOAEL Lowest Observed Adverse Effect Level
NOAEL No Observed Adverse Effect Level
NOAEL No Observable Adverse Effect Level
LOEL Lowest Observed Effect Level
NOEL No Observed Effect Level
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • systemic adverse effect
    Àü½Å¼º ºÎÀÛ¿ë
  • observed value
    °üÃøÄ¡
  • adverse action
    À¯ÇØÀÛ¿ë
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • adverse event
    À¯ÇØ »ç·Ê
  • adverse loading
    À¯ÇØ ÇÏÁß, ÇØ·Î¿î ÇÏÁß
  • adverse selection
    ¿ª ¼±ÅÃ
  • acceptable noise level
    Çã¿ë ¼ÒÀ½
  • adaptation level
    ÀûÀÀ ¼öÁØ
  • anterior palate vault level
    Àü±¸°³Á¤ ³ôÀÌ
  • antimicrobial level
    Ç×±ÕÁ¦Ä¡
  • blood alcohol level
    Ç÷Áß ¾ËÄÚ¿Ã ³óµµ
  • blood oxygenation level dependant
    Ç÷Áß »ê¼ÒÄ¡ ÀÇÁ¸
  • c-AMP level
    ȯ½Ä AMP ·¹º§
  • carinal level
    ºÐ±â ´ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
no-observed-adverse-effect level The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed)
(12 Dec 1998)
adverse effect This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical.
(09 Oct 1997)
adverse Harmful.
(18 Nov 1997)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
adverse event A toxic reaction to a medical therapy.
(09 Oct 1997)
adverse reaction Any undesirable or unwanted consequence of a preventive, diagnostic, or therapeutic procedure or regimen.
(05 Mar 2000)
event, adverse In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug.
(12 Dec 1998)
ACE level <investigation> This is a blood test which measures the concentration of angiotensin-converting enzyme (ACE) in the bloodstream.
Elevations in angiotensin-converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy.
The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels).
(15 Jan 1998)
acoustic reference level The biological reference level for sound measurements. When the term decibel is used to indicate the noise level, a reference quantity is implied; this reference value is usually expressed as a sound pressure of 20 micronewtons per square meter. The reference level is referred to as 0 decibels, the baseline of the scale of noise level's; this baseline is considered the weakest sound that can be heard by a person with very good hearing in an extremely quiet location. Other equivalent reference level's still being used include 0.0002 microbar and 0.0002 dyne per square centimeter.
(05 Mar 2000)
background level The average amount of a substance present in the environment. Originally referring to naturally occurring phenomena. Used in toxic substance monitoring.
(05 Dec 1998)
blood porphyrin level A test which is used to measure red blood cell porphyrin levels. Porphyrins are pigments found in both animal and plant life.
This test is useful in evaluating any number of porphyrin disorders (involving the various porphyrins) of red blood cells.
Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia.
Increased protoporphyrins may be seen in infection, thalassaemia, sideroblastic anaemia, iron deficient anaemia, increased erythropoiesis and lead poisoning. Increased uroporphyrins may indicate congenital erythropoietic porphyria or erythropoietic protoporphyria.
(27 Sep 1997)
carbon dioxide blood level A measure of the bicarbonate level in the blood based on a venipuncture specimen. The serum carbon dioxide is one of the normally reported values in the electrolytes profile. Lower levels of carbon dioxide indicate an acidosis. The normal level is 20 to 29 mEq/L. Lower than normal levels can indicate diabetic ketoacidosis, lactic acidosis, alcoholic ketoacidosis, kidney disease, renal failure, diarrhoea, Addison's disease, ethylene glycol poisoning or methanol poisoning. Greater than normal levels can be seen with excessive vomiting, hyperaldosteronism and Cushing's syndrome.
(27 Sep 1997)
vasopressin level This test measures the amount of ADH in the serum. It is used to detect disorders that may affect the level of ADH in the serum. Normal values are: 0 to 4.7 pg/ml. Elevated ADH levels can indicate a CNS infection, fluid imbalance, CNS tumour, SIADH or acute porphyria. Low levels can indicate: diabetes insipidus or damage to the pituitary gland.
(27 Sep 1997)
maximum permissible exposure level The highest level of exposure to a substance, usually noxious, in the environment or during diagnostic and therapeutic procedures, that a body can tolerate without injury.
(12 Dec 1998)
mean sea level <marine biology> A tidal datum: the arithmetic mean of hourly water elevations observed over a specific 19-year cycle. Points on land can be referenced to a mean sea level, in which case the datum assumes zero elevation.
(09 Oct 1997)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
no observed adverse effect level is the highest tested dose or concentration of a substance which resulted in no observed adverse effect in exposed test organisms where higher doses or concentrations resulted in an adverse effect.
Ãâó: www.setonresourcecenter.com/cfr/40CFR/P132_003.HTM
no observed adverse effect level Greatest concentration or amount of an agent, found by experiment or observation, that causes no detectable adverse alteration of morphology, functional capacity, growth, development or life span in an organism, system or (sub) population.
Ãâó: www.fsra.net/glossary.html
no observed adverse effect level The dose of a chemical at which there is no increase in the frequency or severity of adverse effects noted in an exposed population.
Ãâó: www.dow.com/productsafety/overview/glossary.htm
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse
    ¿ªÀÇ, ºÒ¿îÇÑ, ¹Ý´ëÇÏ´Â
  • adverse
    ¿ªÀÇ;°Å²Ù·ÎÀÇ;¹Ý´ëÀÇ;ÀûÀǰ¡ ÀÖ´Â;ºÒ¸®ÇÑ
  • level
    ÆòÆòÇÑ,¼öÆò,¼öÁØ,ÆòÆòÇÏ°Ô ÇÏ´Ù
  • A level
    »ó±ÞÇгâ½ÃÇè
  • O-level
    ±âÃÊÇз½ÃÇè
  • club floor(level)
    (È£ÅÚÀÇ)±Íºó¿ë Ç÷ξî;ȣȭ°´½ÇÇ÷ξî(º¸Åë È£ÅÚÀÇ ÃÖ»óÃþ)
  • constant-level balloon
    Á¤ °íµµ±â±¸
  • dumpy level
    ¸Á¿ø°æÀÌ ´Þ¸° ¼öÁرâ
  • fog level
    (Çö»óµÈ Çʸ§ÀÇ) ¹Ì³ëÃâ ³óµµ
  • level
    ¼öÆòÀÇ;ÆòÆòÇÑ;µ¿ÀÏ ¼öÁØÀÇ;¼­·Î ¿ì¿­ÀÌ ¾ø´Â;ÇѰᰰÀº;ºÐº°ÀÖ´Â;do one's ~ best Àü·ÂÀ» ´ÙÇÏ´Ù
  • level
    ¼öÆò(¸é);ÆòÁö;³ôÀÌ;¼öÁØ;find one's(its)~ ½Ç·Â¿¡ ¸Â´Â ÁöÀ§¸¦ ¾ò´Ù;on a ~ with ...°ú µ¿µîÇϰÔ;on the ~ °øÁ¤ÇÑ
  • level
    °Ü´©´Ù;Á¶ÁØÇÏ´Ù;~ down(up)(...ÀÇ Ç¥ÁØÀ») ³·Ãß´Ù(¿Ã¸®´Ù)
  • level
    ¼öÆòÀ¸·Î ¸¸µé´Ù;°í¸£´Ù;µ¿ÀÏ ¼öÁØÀ¸·Î ¸¸µé´Ù;(°Ç¹°À») ¾²·¯¶ß¸®´Ù;(Àǵµ¸¦) µ¹¸®´Ù
  • mean sea level
    Æò±Õ ÇØ¸é(ÇØ¹ß ±âÁØ)
  • ordinary level
    G;C;E;ÀÇ ±âÃÊ Çз ½ÃÇè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á